Market Research Logo

Colorectal Cancer Therapeutics in Major Developed Markets to 2020 - Increased Uptake of High Priced Drugs to Offset the Impact of Generics

Colorectal Cancer Therapeutics in Major Developed Markets to 2020 - Increased Uptake of High Priced Drugs to Offset the Impact of Generics

Summary

GBI Research, the leading business intelligence provider, has released its latest research, “Colorectal Cancer Therapeutics in Major Developed Markets to 2020 - Increased Uptake of High Priced Drugs to Offset the Impact of Generics”, which provides in-depth analysis of the Colorectal Cancer (CRC) therapeutics market in the eight major geographies of the US, Canada, the UK, France, Germany, Spain, Italy and Japan. The report provides an estimation of the market size for 2013, along with market forecast until 2020. It also covers disease epidemiology, treatment algorithms, treatment patterns, in-depth pipeline analysis, and deal analysis.

The CRC therapeutics market in the eight major markets is expected to grow at a Compound Annual Growth Rate (CAGR) of 1.8% to $9.4 billion by 2020. The US had the largest market share in 2013, equivalent to a global share of 44.1%, followed by Japan and Germany with 14.7% and 11.9% respectively. Spain had the lowest market share of the leading eight at 4.1%. All markets covered in the report are expected to witness a slower growth rate than Japan, which will grow at a CAGR of 5%. However, this moderate growth will be stymied by the expected uptake of lower-priced biosimilar versions of bevacizumab and cetuximab due to the expiration of the patents of Avastin and Erbitux in the latter half of the forecast period. Also expected is the launch of generic versions of capecitabine, which will also affect the market. However, this will be offset by the launch of premium-priced emerging therapies. Stivarga is expected to be one of the biggest drivers of growth in the CRC market, primarily due to its expected line extension in the first-line metastatic setting as a maintenance treatment for patients with resected liver metastases. The launch of Lonsurf (TAS-102), approved in Japan in 2014, in the third- and fourth-line settings will further increase the pharmacological treatment rates in these lines, which will give patients a more tolerable alternative to Stivarga. The moderate uptake of other late-stage pipeline products, panitumumab and Xilonix, following their expected approval, is expected to drive additional growth within this market.

The CRC pipeline is highly robust, with potential drug candidates across various Phases of clinical development. With nearly 400 active pipeline molecules, the majority of the investigational drug candidates are being evaluated for the treatment of CRC in advanced stages, either as first-line or second-line therapies. The current investigational pipeline candidates include new combination therapies and targeted therapies, as well as promising immunotherapies and chemotherapy drug candidates. As well as these active progressing pipeline molecules, the pipeline also includes nearly 180 molecules that are either inactive or discontinued.

Scope

The report analyzes treatment usage patterns, market characterization, the pipeline, and key licensing and co-development deals in the eight major markets: the US, the UK, France, Germany, Spain, Italy, Japan and Canada. It includes -

  • A brief introduction to CRC, including the disease’s pathogenesis, etiology, diagnosis and treatment algorithms
  • In-depth analysis of currently marketed drugs for CRC, examining their safety, efficacy, treatment patterns and strengths/weaknesses and including a heat map that compares the drugs in terms of safety and efficacy
  • A comprehensive review of the pipeline for CRC, including individual analysis of a number of late-stage pipeline drugs that are likely to enter the market during the forecast period; the pipeline is analyzed on the basis of Phase distribution, molecule type, program type, mechanism of action and molecular target
  • Additional in-depth analysis of pipeline drug clinical trials by Phase, trial size, trial duration and program failure rate for each molecule type
  • Multi-scenario forecast data of the market to 2020, taking into account how the market may be affected by the introduction of new drugs, the expiry of key patents on current drugs and the changes in disease epidemiology across the key developed markets
  • Discussion of the drivers of and barriers to market growth
  • In-depth analysis of all licensing and co-development deals that have occurred in the CRC market since 2006
Reasons to buy

The report will enhance your decision-making capability by allowing you to -
  • Understand the CRC pipeline and the factors that indicate that it is becoming more innovative
  • Examine detailed profiles of promising pipeline products and gain an insight into how they are likely to compete in the market and who their main competitors will be
  • Follow the trends in CRC clinical trial size and duration in relation to industry averages and assess the potential risk of future developmental programs according to mechanism of action by considering the recorded clinical trial failure rates
  • Observe the potential growth patterns expected for the CRC market over the forecast period, identify which countries are expected to make the biggest contribution to this growth, and devise a more effective country strategy through an understanding of key drivers and barriers in the CRC market
  • Accelerate and strengthen your market position by identifying key companies for strategic partnerships


Colorectal Cancer Treatment Market Value to Hit $9.4 Billion by 2020, says GBI Research

Reference Code: GBIHC352MR

Publication Date: January 2015


The value of the Colorectal Cancer (CRC) therapeutics market will increase moderately, from $8.3 billion in 2013 to $9.4 billion by 2020, representing a Compound Annual Growth Rate (CAGR) of 1.8%, according to business intelligence provider GBI Research.

The company’s latest report* states that this growth, which will occur across eight major developed countries, namely the US, UK, France, Germany, Spain, Italy, Japan and Canada, will be limited by the patent expirations of Avastin and Erbitux during the forecast period, which will prompt the uptake of lower-priced biosimilar versions of these drugs.

However, Saurabh Sharma, Senior Analyst for GBI Research, says that despite its patent expiration, Avastin is expected to retain its market-leading position in the global CRC space through to 2020.

Sharma explains: “Avastin is heavily prescribed in both first- and second-line settings, regardless of the patient’s K-Ras status. Its dominance is consistent across both the metastatic K-Ras wild-type and mutation-positive settings, despite the availability of epidermal growth factor receptor inhibitors for the treatment of K-Ras wild-type disease.

“Additionally, Stivarga is expected to be one of the biggest drivers of growth in the CRC market, due primarily to its anticipated line extension as a maintenance treatment in the first-line metastatic setting for patients with resected liver metastases.”

The analyst adds that while multiple new pipeline agents are expected to be launched in the CRC therapeutics market over the forecast period, none of these drugs will have a dramatic impact on the overall arena.

Sharma continues: “The currently marketed brands will continue to enjoy dominance due to their incorporation in the earlier and more lucrative lines of treatment.

“A number of new agents are likely to enter the market, including the anti-angiogenesis inhibitors Cyramza and nintedanib. However, these drugs will enter the competitive second- and later-line metastatic segments of the CRC therapeutics space.”

*Colorectal Cancer Therapeutics in Major Developed Markets to 2020 - Increased Uptake of High Priced Drugs to Offset the Impact of Generics

This report provides analysis of colorectal cancer treatment usage patterns, market characterization, the pipeline, and key licensing and co-development deals in eight major markets, namely the US, UK, France, Germany, Spain, Italy, Japan and Canada. The report includes annualized historic and forecast data from 2013 through to 2020.

This report was built using data and information sourced from proprietary databases, primary and secondary research, and in-house analysis conducted by GBI Research’s team of industry experts.

  • GBI Research Report Guidance
  • Executive Summary
    • Table Colorectal Cancer Therapeutics, Global, Market Size ($bn), 2013-2020
    • Table Colorectal Cancer Therapeutics, Global, Pipeline by Stage of Development and Program Type, 2013
  • Introduction
    • Colorectal Cancer
    • Symptoms
    • Epidemiology
    • Pathophysiology
      • Histology
      • Genetic Basis
      • Etiology of Colorectal Cancer
    • Diagnosis
      • Digital Rectal Examination
      • Fecal Occult Blood Test
      • Flexible Sigmoidoscopy
      • Colonoscopy
      • Virtual Colonoscopy
      • Double Contrast Barium Enema
    • Prognosis and Disease Staging
      • Table Colorectal Cancer Therapeutics, Global, TNM Staging, 2013
    • Treatment Options
      • Surgery and Radiation Therapy
        • Table Surgical Options for Colorectal Cancer
      • Chemotherapy
      • Targeted Therapies
      • Resistance to Pharmacological Therapies
      • Treatment Guidelines
        • Table Figure 1: Colorectal Cancer Therapeutics, Global, European Society for Medical Oncology Treatment Guidelines (Colorectal Cancer at Stage I to III)
        • Table Figure 2: Colorectal Cancer Therapeutics, Global, European Society for Medical Oncology Treatment Guidelines (Colorectal Cancer at Stage IV)
  • Marketed Products
    • Key Marketed Products
      • Immunotherapies
      • Targeted Therapies
      • Hyperthermic Intraperitoneal Chemotherapy
    • Heat Map for Marketed Products
      • Table Figure 3: Colorectal Cancer Therapeutics, Global, Heat Map (Marketed Products)
  • Pipeline Analysis
    • Overall Pipeline
      • Table Figure 4: Colorectal Cancer Therapeutics, Global, Pipeline by Stage of Development and Program Type, 2014
    • Pipeline Analysis by Molecule Type
      • Table Figure 5: Colorectal Cancer Therapeutics, Global, Pipeline by Molecule Type and Stage of Development, 2014
    • Pipeline Analysis by Mechanism of Action
      • Table Figure 6: Colorectal Cancer Therapeutics, Global, Pipeline by Mechanism of Action and Stage of Development, 2014
    • Clinical Trials
    • Failure Rate
      • Table Figure 7: Colorectal Cancer Therapeutics, Global, Clinical Trial Failure Rate (%), 2014
    • Clinical Trial Size
      • Table Figure 8: Colorectal Cancer Therapeutics, Global, Clinical Trial Size, 2014
    • Duration
      • Table Figure 9: Colorectal Cancer Therapeutics, Global, Clinical Trial Duration (months), 2014
    • Promising Drug Candidates in Pipeline
      • Lonsurf (TAS-102 (tipiracil + trifluridine)) - Taiho Pharmaceutical
      • Cyramza - ramucirumab - Eli Lilly and Company
      • TS-1/Teysuno (tegafur + gimeracil + oteracil) - Taiho Pharmaceutical
      • CPP-1X (eflornithine hydrochloride) + sulindac - Cancer Prevention Pharmaceuticals
      • MelCancerVac - DanDrit Biotech
      • Xilonix - XBiotech
      • Nintedanib - Boehringer Ingelheim
  • Market Forecast to 2020
    • Global Market
      • Treatment Use Patterns
      • Market Size
        • Table Figure 10: Colorectal Cancer Therapeutics, Global, Treatment Use Patterns (`000) and Market Size ($bn), 2013-2020
    • North America
      • Treatment Use Patterns
        • Table Figure 11: Colorectal Cancer Therapeutics, US and Canada, Treatment Use Patterns (`000), 2013-2020
      • Annual Cost of Therapy
        • Table Figure 12: Colorectal Cancer Therapeutics, US and Canada, Annual Cost of Therapy ($), 2013-2020
      • Market Size
        • Table Figure 13: Colorectal Cancer Therapeutics, US and Canada, Market Size ($m), 2013-2020
    • Top Five European Markets
      • Treatment Use Patterns
        • Table Figure 14: Colorectal Cancer Therapeutics, Top Five European Markets, Treatment Use Patterns (`000), 2013-2020
      • Annual Cost of Therapy
        • Table Figure 15: Colorectal Cancer Therapeutics, Top Five European Markets, Annual Cost of Therapy ($), 2013-2020
      • Market Size
        • Table Figure 16: Colorectal Cancer Therapeutics, Top Five European Markets, Market Size ($m), 2013-2020
    • Japan
      • Treatment Use Patterns
        • Table Figure 17: Colorectal Cancer Therapeutics, Japan, Treatment Use Pattern, 2013-2020
      • Annual Cost of Therapy
        • Table Figure 18: Colorectal Cancer Therapeutics, Japan, Annual Cost of Therapy, 2013-2020
      • Market Size
        • Table Figure 19: Colorectal Cancer Therapeutics, Japan, Market Size ($m), 2013-2020
    • Drivers and Barriers for the Colorectal Cancer Therapeutics in Major Developed Markets to 2020
      • Drivers
      • Barriers
  • Deals and Strategic Consolidations
    • Licensing Agreements
      • Table Figure 20: Colorectal Cancer Therapeutics, Global, Licensing Deals by Geography, 2006-2014
      • Table Figure 21: Colorectal Cancer Therapeutics, Global, Licensing Deals by Phase, Value, Mechanism of Action, 2006-2014
      • Major Licensing Deals
    • Co-development Agreements
      • Table Figure 22: Colorectal Cancer Market, Global, Co-development Deals by Geography and by Value, 2006-2014
      • Major Co-development Agreements
  • Appendix
    • All Pipeline Drugs by Phase
      • Discovery
        • Table Colorectal Cancer Therapeutics, Global, All Pipeline Products (Discovery), 2014
      • Preclinical
        • Table Colorectal Cancer Therapeutics, Global, All Pipeline Products (Preclinical), 2014
      • IND/CTA-Filed
        • Table Colorectal Cancer Therapeutics, Global, All Pipeline Products (IND/CTA-Filed), 2014
      • Phase I
        • Table Colorectal Cancer Therapeutics, Global, All Pipeline Products (Phase I), 2014
      • Phase II
        • Table Colorectal Cancer Therapeutics, Global, All Pipeline Products (Phase II), 2014
      • Phase III
        • Table Colorectal Cancer Therapeutics, Global, All Pipeline Products (Phase III), 2014
    • Market Forecasts to 2020
      • Global
        • Table Colorectal Cancer Therapeutics, Global, Forecast Data, 2013-2020
      • US
        • Table Colorectal Cancer Therapeutics, US, Forecast Data, 2013-2020
      • Canada
        • Table Colorectal Cancer Therapeutics, Canada, Forecast Data, 2013-2020
      • UK
        • Table Colorectal Cancer Therapeutics, UK, Forecast Data, 2013-2020
      • France
        • Table Colorectal Cancer Therapeutics, France, Forecast Data, 2013-2020
      • Germany
        • Table Colorectal Cancer Therapeutics, Germany, Forecast Data, 2013-2020
      • Italy
        • Table Colorectal Cancer Therapeutics, Italy, Forecast Data, 2013-2020
      • Spain
        • Table Colorectal Cancer Therapeutics, Spain, Forecast Data, 2013-2020
      • Japan
        • Table Colorectal Cancer Therapeutics, Japan, Forecast Data, 2013-2020
    • Market Definitions
    • Abbreviations
    • References
    • References for Heat Map
      • Table Colorectal Cancer Market, References for Heat Map
    • Research Methodology
      • Coverage
      • Secondary Research
      • Primary Research
      • Therapeutic Landscape
        • Table Figure 23: GBI Research Market Forecasting Model
      • Geographical Landscape
      • Pipeline Analysis
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report